Clinical Trial Update: A Study Of The Selective PKC-β Inhibitor MS- 553 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of the selective PKC-β inhibitor MS-553 in chronic lymphocytic leukemia, small lymphocytic lymphoma, and aggressive lymphoma was terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Lymphoma
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• MS-553 (MS-553)

Snippet

Sponsor: MingSight Pharmaceuticals, Inc | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-04-10